Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | ET-A ↓ ↑ | ET-B ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BQ-123 |
+++
Endothelin A receptor, IC50: 7.3 nM |
98% | |||||||||||||||||
Macitentan |
++++
ET-A, IC50: 0.5 nM |
+
ET-B, IC50: 391 nM |
98% | ||||||||||||||||
Zibotentan |
++
ET-A, IC50: 21 nM |
99%+ | |||||||||||||||||
Bosentan hydrate |
+++
ET-A, Ki: 4.7 nM |
++
ET-B, Ki: 95 nM |
98% | ||||||||||||||||
Ambrisentan | ✔ | 98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Endothelin receptors are G protein-coupled receptors (GPCRs) of the β-group of rhodopsin receptors. It can bind to at least four endothelin ligands, ETA, ETB (ETB1, ETB2) and ETC [3]. Zibotentan (ZD4054) potently inhibited the binding of 125iodine-ET-1 to cloned human ETA expressed in mouse erythroleukaemic cells, with the pIC50 of 8.27 nM, but had no measurable affinity (pIC50>10 μM) for ETB [4]. Treatment with 1 μM Zibotentan for 24 hours inhibited proliferation of serum-starved HEY, OVCA 433, SKOV-3, and A-2780 cells. And Zibotentan at 1 μM decreased the endogenous ET-1-induced phosphorylation/activation of both kinases (AKT and p42/44MAPK) in HEY cells [5]. After oral administration of Zibotentan at a dose of ~3 mg/kg/d for 31days, MBP, SBP and DBP of the rats with hypertension decreased by 5.90 (4.75–7.05) mmHg, 5.91 (4.70–7.11) mmHg and 5.69 (4.26–7.12) mmHg, respectively, and the HR and RR rose by 9.23 (6.21–12.3) bpm and 4.62 (1.89–7.35) br/min, respectively [6]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00055471 | - | Completed | - | - | |
NCT00055471 | Prostatic Neoplasms ... 展开 >> Metastases, Neoplasm 收起 << | Phase 2 | Completed | - | United States, Ohio ... 展开 >> Research Site Cleveland, Ohio, United States, 44195 United States, Wisconsin Research Site Madison, Wisconsin, United States 收起 << |
NCT00929162 | Patients With Advanced Ovarian... 展开 >> Cancer Sensitive to Platinum-based Chemotherapy 收起 << | Phase 2 | Terminated(Primary objective o... 展开 >>f the trial was not met and so there was no benefit in collecting further information) 收起 << | - | Germany ... 展开 >> Research Site Berlin, Germany Research Site Dresden, Germany Research Site Dusseldorf, Germany Research Site Essen, Germany Research Site Karlsruhe, Germany Research Site Kassel, Germany Research Site Kiel, Germany Research Site Lich, Germany Research Site Magdeburg, Germany Research Site Marburg, Germany Research Site Munchen, Germany Research Site Rostock, Germany Research Site Wiesbaden, Germany Italy Research Site Milano, MI, Italy Research Site Perugia, PG, Italy Research Site Aviano, PN, Italy Research Site Campobasso, Italy Research Site Modena, Italy Research Site Napoli, Italy Research Site Roma, Italy 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.36mL 0.47mL 0.24mL |
11.78mL 2.36mL 1.18mL |
23.56mL 4.71mL 2.36mL |
CAS号 | 186497-07-4 |
分子式 | C19H16N6O4S |
分子量 | 424.433 |
别名 | ZD4054 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Room temperature |
溶解度 |
DMSO: 25 mg/mL(58.9 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |